Abstract
There is a renewed interest in the ultimate role of fatty acid synthase (FASN)--a key lipogenic enzyme catalysing the terminal steps in the de novo biogenesis of fatty acids--in cancer pathogenesis. Tumour-associated FASN, by conferring growth and survival advantages rather than functioning as an anabolic energy-storage pathway, appears to necessarily accompany the natural history of most human cancers. A recent identification of cross-talk between FASN and well-established cancer-controlling networks begins to delineate the oncogenic nature of FASN-driven lipogenesis. FASN, a nearly-universal druggable target in many human carcinomas and their precursor lesions, offers new therapeutic opportunities for metabolically treating and preventing cancer.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
AMP-Activated Protein Kinases
-
Antineoplastic Agents / pharmacology
-
Carcinoma in Situ / pathology
-
Cell Death / genetics
-
Fatty Acid Synthases / antagonists & inhibitors
-
Fatty Acid Synthases / metabolism*
-
Fatty Acids / biosynthesis
-
Genes, BRCA1
-
Glucose / metabolism
-
Humans
-
Lipogenesis / genetics*
-
Multienzyme Complexes / metabolism
-
Neoplasm Invasiveness
-
Neoplasm Metastasis
-
Neoplasms / drug therapy
-
Neoplasms / enzymology*
-
Neoplasms / genetics*
-
Neoplasms / pathology
-
Nuclear Proteins / genetics
-
Phenotype*
-
Protein Serine-Threonine Kinases / metabolism
-
Sterol Regulatory Element Binding Protein 1 / metabolism
-
Transcription Factors / genetics
Substances
-
Antineoplastic Agents
-
Fatty Acids
-
Multienzyme Complexes
-
Nuclear Proteins
-
Sterol Regulatory Element Binding Protein 1
-
THRSP protein, human
-
Transcription Factors
-
Fatty Acid Synthases
-
Protein Serine-Threonine Kinases
-
AMP-Activated Protein Kinases
-
Glucose